These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12086881)

  • 1. Of mice and women.
    Foulkes WD
    Cancer Cell; 2002 Feb; 1(1):11-2. PubMed ID: 12086881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.
    Orsulic S; Li Y; Soslow RA; Vitale-Cross LA; Gutkind JS; Varmus HE
    Cancer Cell; 2002 Feb; 1(1):53-62. PubMed ID: 12086888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse model may demystify ovarian cancer.
    Schub T
    Lab Anim (NY); 2002 Apr; 31(4):12. PubMed ID: 14619841
    [No Abstract]   [Full Text] [Related]  

  • 4. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.
    King BL; Carter D; Foellmer HG; Kacinski BM
    Am J Pathol; 1992 Jan; 140(1):23-31. PubMed ID: 1346236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically-defined ovarian cancer mouse models.
    Morin PJ; Weeraratna AT
    J Pathol; 2016 Jan; 238(2):180-4. PubMed ID: 26496815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocompetent mouse model of ovarian cancer for in vivo imaging.
    Nunez-Cruz S; Scholler N
    Methods Mol Biol; 2013; 1049():425-33. PubMed ID: 23913235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of Ovarian Neoplasms in Genetically Modified Mice.
    Nikitin AY; Connolly DC; Hamilton TC
    Comp Med; 2004 Feb; 54(1):26-8. PubMed ID: 15382342
    [No Abstract]   [Full Text] [Related]  

  • 8. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
    Xing D; Orsulic S
    Cancer Res; 2006 Sep; 66(18):8949-53. PubMed ID: 16982732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular signatures in ovarian carcinoma].
    Singer G
    Praxis (Bern 1994); 2005 Oct; 94(40):1561-3. PubMed ID: 16245918
    [No Abstract]   [Full Text] [Related]  

  • 11. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
    Mahasreshti PJ; Navarro JG; Kataram M; Wang MH; Carey D; Siegal GP; Barnes MN; Nettelbeck DM; Alvarez RD; Hemminki A; Curiel DT
    Clin Cancer Res; 2001 Jul; 7(7):2057-66. PubMed ID: 11448924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically engineered mouse models of ovarian cancer and their utility in drug discovery.
    Sale S
    Curr Protoc Pharmacol; 2009 Jun; Chapter 14():Unit14.11. PubMed ID: 22294391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
    Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A ret transgenic mouse model of thyroid carcinogenesis.
    Capen C; Sagartz J
    Lab Anim Sci; 1998 Dec; 48(6):580-3. PubMed ID: 10090080
    [No Abstract]   [Full Text] [Related]  

  • 16. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
    Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice.
    Cai KQ; Wang Y; Smith ER; Smedberg JL; Yang DH; Yang WL; Xu XX
    Neoplasia; 2015 Jan; 17(1):89-100. PubMed ID: 25622902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.
    Tang FH; Hsieh TH; Hsu CY; Lin HY; Long CY; Cheng KH; Tsai EM
    Int J Cancer; 2017 Apr; 140(8):1860-1869. PubMed ID: 28032649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells].
    Marth C; Müller-Holzner E; Zeimet AG; Greiter E; Cronauer MV; Doppler W; Eibl B; Hynes NE; Daxenbichler G
    Gynakol Geburtshilfliche Rundsch; 1992; 32(1):31-4. PubMed ID: 1355379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
    Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.